Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Urovant, Now under Sumitomo Dainippon, Seeks US Approval for Vibegron
January 7, 2020
- Eisai Discontinues Development of Epilepsy Drug after Death in PI; “Will Never Be Administered to Humans in the Future”
January 6, 2020
- Astellas Snaps Up US Biotech Xyphos for I/O Technology Platform
January 6, 2020
- Maruho Becomes Solasia’s 2nd Largest Shareholder
January 6, 2020
- Chugai’s Companion Diagnostic OK’ed for Rozlytrek’s ROS1 Use
December 27, 2019
- I/O Biotech BrightPath, Osaka Univ. Link Up for R&D of Immunostimulants
December 27, 2019
- Xofluza Most Detailed Drug for GPs in November: Impact Track
December 26, 2019
- IBL Inks Tick-Borne Disease Deal with South Korea Firm
December 26, 2019
- Nippon BI Chair Thorsten Poehl to Double as President after Merger; Yoshiaki Aono to Head Pharma Biz
December 26, 2019
- Fujifilm PII Alzheimer’s Study Gets Underway in Europe
December 26, 2019
- Opdivo/Yervoy Combo Filed for Frontline NSCLC in Japan
December 26, 2019
- Kyowa Hakko Bio Hit with 18-Day Biz Suspension over GMP Failings
December 25, 2019
- 15% Share Eyed for Jointly Developed Symbicort Generics, Toa Set to Push Uptake with Support App
December 25, 2019
- Gilead Japan Hooks Up with Arthritis-Savvy Eisai for JAK Inhibitor
December 25, 2019
- ASKA Files Uterine Fibroid Drug in Japan
December 25, 2019
- Renascience, ASKA Pair Up to Develop Pyridoxamine
December 25, 2019
- Sosei, Pfizer Nominate 3rd Development Candidate Compound
December 25, 2019
- Towa to Acquire Spanish Generic Player, Set to Venture into US/European Markets
December 24, 2019
- Eisai’s Insomnia Drug Grabs US Approval, Japan Nod Expected Soon
December 24, 2019
- US FDA Accepts Resubmission for Sunovion’s Parkinson’s Med
December 24, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…